Humira, Cimzia Arthritis Indications May Rest On Adequacy Of Classification Criteria
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Arthritis Advisory Committee will consider whether axial spondyloarthritis can serve as the basis for a new indication for AbbVie and UCB’s TNF inhibitors. Agency’s briefing documents raise concerns that classification criteria used in pivotal studies capture a patient population that is too broad and heterogeneous.
You may also be interested in...
FDA Biosimilars Chief Leah Christl Joining Amgen; Agency Veteran Sarah Yim Takes Her Place
Christl joins Amgen's policy team in Washington, DC. Yim was reviewer for Inflectra and Amjevita biosimilars.
Arthritis Patient Classification To Be Key Issue In TNF Inhibitor Reviews
FDA’s Arthritis Advisory Committee will meet July 22 to give its views on how identification criteria for axial spondyloarthritis impacts approval of drugs for the disease; sBLAs seeking the indication for AbbVie’s Humira and UCB’s Cimzia are pending at the agency.
Humira Shows Benefit In New Arthritis Indications Based On Novel Criteria
Abbott’s anti-TNF demonstrated an improvement in two subsets of spondyloarthritis patients using new criteria developed by the SpondyloArthritis International Society to identify and test patients.